HK1134436A1 - N-(arylamino)-sulfonamide inhibitors of mek mek - Google Patents
N-(arylamino)-sulfonamide inhibitors of mek mekInfo
- Publication number
- HK1134436A1 HK1134436A1 HK10100120.1A HK10100120A HK1134436A1 HK 1134436 A1 HK1134436 A1 HK 1134436A1 HK 10100120 A HK10100120 A HK 10100120A HK 1134436 A1 HK1134436 A1 HK 1134436A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mek
- arylamino
- sulfonamide inhibitors
- sulfonamide
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70181405P | 2005-07-21 | 2005-07-21 | |
US70671905P | 2005-08-08 | 2005-08-08 | |
US73163305P | 2005-10-28 | 2005-10-28 | |
PCT/US2006/028326 WO2007014011A2 (en) | 2005-07-21 | 2006-07-21 | N-(arylamino)-sulfonamide inhibitors of mek |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1134436A1 true HK1134436A1 (en) | 2010-04-30 |
Family
ID=37683815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10100120.1A HK1134436A1 (en) | 2005-07-21 | 2010-01-07 | N-(arylamino)-sulfonamide inhibitors of mek mek |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1912636B1 (de) |
KR (1) | KR101377688B1 (de) |
AU (1) | AU2006272837B2 (de) |
CA (1) | CA2618218C (de) |
CY (1) | CY1118055T1 (de) |
DK (1) | DK1912636T3 (de) |
ES (1) | ES2481402T3 (de) |
HK (1) | HK1134436A1 (de) |
IL (1) | IL189201A (de) |
MX (1) | MX2008002114A (de) |
PL (1) | PL1912636T3 (de) |
PT (1) | PT1912636E (de) |
WO (1) | WO2007014011A2 (de) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
WO2009018233A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
AU2008206045A1 (en) * | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
UA97834C2 (ru) | 2007-04-18 | 2012-03-26 | Пфайзер Продактс Инк. | Производные сульфониламида для лечения анормального роста клеток |
EP2155659A1 (de) * | 2007-05-11 | 2010-02-24 | Bayer Schering Pharma Aktiengesellschaft | Substituierte phenylaminbenzen-derivate zur behandlung hyperproliferativer und durch extrazelluläre mitrogenkinase-aktivität hervorgerufener erkrankungen |
KR101511396B1 (ko) | 2007-07-20 | 2015-04-13 | 추가이 세이야쿠 가부시키가이샤 | p27 단백질 유도제 |
JP5479337B2 (ja) * | 2007-07-30 | 2014-04-23 | アルディア バイオサイエンス,インク. | Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用 |
US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
TWI481590B (zh) * | 2008-03-06 | 2015-04-21 | Ardea Biosciences Inc | 作為mek抑制劑之n-(芳胺基)磺醯胺(包括多晶型)衍生物及組合物,使用方法及其製備方法 |
AU2009236325A1 (en) * | 2008-04-14 | 2009-10-22 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
EP2279166A1 (de) * | 2008-04-22 | 2011-02-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte phenoxybenzamide |
EP2346818B1 (de) | 2008-11-10 | 2012-12-05 | Bayer Intellectual Property GmbH | Substituierte sulfonamidophenoxybenzamide |
EP2356091A2 (de) * | 2008-11-10 | 2011-08-17 | Bayer Schering Pharma AG | Substituierte amidophenoxybenzamide |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
MX2011009498A (es) | 2009-03-11 | 2011-10-14 | Ardea Biosciences Inc | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos. |
EP2411366B8 (de) * | 2009-03-27 | 2015-07-15 | Ardea Biosciences, Inc. | Dihydropyridin sulfonamide und dihydropyridin sulfamide als mek hemmer |
US9034861B2 (en) | 2009-10-13 | 2015-05-19 | Allomek Therapeutics Llc | MEK inhibitors useful in the treatment of diseases |
US20120269803A1 (en) | 2009-10-21 | 2012-10-25 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
MY156209A (en) | 2009-11-04 | 2016-01-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful mek inhibitors |
CR20170159A (es) | 2009-12-01 | 2017-06-26 | Abbvie Inc | Nuevos compuestos tricíclicos |
CA2789696C (en) | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
JP5985401B2 (ja) | 2010-03-09 | 2016-09-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 |
EP2558126A2 (de) * | 2010-04-16 | 2013-02-20 | Bayer Intellectual Property GmbH | Substituierte 2,3-dihydroimidazo[1,2-c]chinazolin-haltige kombinationen |
WO2012041987A1 (en) * | 2010-10-01 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
CN104011039A (zh) * | 2011-12-19 | 2014-08-27 | 住友化学株式会社 | 磺酸盐的制造方法 |
JP6158833B2 (ja) | 2012-01-09 | 2017-07-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | ベータ−カテニン関連疾患を処置するための有機組成物 |
CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
KR20150013332A (ko) | 2012-05-31 | 2015-02-04 | 바이엘 파마 악티엔게젤샤프트 | 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커 |
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 및 alk2 억제제 및 이들의 사용 방법 |
AP2015008656A0 (en) | 2013-03-15 | 2015-08-31 | Novartis Ag | Antibody drug conjugates |
EP2848246A1 (de) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzungen enthaltendes Refametinib |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
MX2017001946A (es) | 2014-08-12 | 2017-06-19 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6. |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
EP3200775B1 (de) | 2014-10-03 | 2019-11-20 | Novartis AG | Kombinationstherapien |
AU2015347015B2 (en) | 2014-11-14 | 2019-02-14 | Novartis Ag | Antibody drug conjugates |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
ES2722048T3 (es) | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
AU2016238436A1 (en) | 2015-03-25 | 2017-08-17 | Novartis Ag | Formylated N-heterocyclic derivatives as FGFR4 inhibitors |
EP3310813A1 (de) | 2015-06-17 | 2018-04-25 | Novartis AG | Antikörper-wirkstoff-konjugate |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
US11975002B2 (en) | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
ES2798424T3 (es) | 2016-06-20 | 2020-12-11 | Novartis Ag | Compuestos de triazolopiridina y usos de estos |
US10676479B2 (en) | 2016-06-20 | 2020-06-09 | Novartis Ag | Imidazolepyridine compounds and uses thereof |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
EP3630813A1 (de) | 2017-05-24 | 2020-04-08 | Novartis AG | Antikörper-zytokin- gepfropfte proteine und verfahren zur verwendung in der krebsbehandlung |
EP3630162A1 (de) | 2017-05-24 | 2020-04-08 | Novartis AG | Antikörper-zytokin-gepfropfte proteine und verfahren zur verwendung |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
EP3769765B1 (de) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Pharmazeutische zusammensetzung mit natriumalkylsulfat |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
FI3820573T3 (fi) | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
WO2020021322A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
EP3826684A4 (de) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | Verfahren zur behandlung von mit abnormaler acvr1 -expression verbundenen krankheiten und acvr1 -inhibitoren zur verwendung in demselben |
MX2021001804A (es) | 2018-08-17 | 2021-04-19 | Novartis Ag | Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. |
CN117122707A (zh) | 2018-09-25 | 2023-11-28 | 意大利国际先进加速器应用有限公司 | 联合疗法 |
EP3873532A1 (de) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign-antikörper-arzneimittelkonjugate |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US11712433B2 (en) | 2019-03-22 | 2023-08-01 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
EP3994132A1 (de) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosinkinase-nicht-rezeptor-1(tnk1)-inhibitoren und deren verwendungen |
WO2021057853A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Aza-quinoline compounds and uses thereof |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230165862A1 (en) | 2020-04-10 | 2023-06-01 | Taiho Pharmaceutical Co., Ltd. | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
EP4204021A1 (de) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Verfahren zur behandlung von psma-exprimierenden krebsarten |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040171632A1 (en) * | 1998-12-22 | 2004-09-02 | Gowan Richard Carleton | Combination chemotherapy |
ES2252996T3 (es) | 1999-01-13 | 2006-05-16 | Warner-Lambert Company Llc | Derivados de bencenosulfonamida y su uso como inhibidores de mek. |
DE602004020741D1 (de) | 2003-02-26 | 2009-06-04 | Kowa Co | Mittel zur behandlung der allergischen kontaktdermatitis |
TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
PL2298768T3 (pl) | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu |
-
2006
- 2006-07-21 DK DK06788078.1T patent/DK1912636T3/da active
- 2006-07-21 PL PL06788078T patent/PL1912636T3/pl unknown
- 2006-07-21 PT PT67880781T patent/PT1912636E/pt unknown
- 2006-07-21 MX MX2008002114A patent/MX2008002114A/es active IP Right Grant
- 2006-07-21 CA CA2618218A patent/CA2618218C/en not_active Expired - Fee Related
- 2006-07-21 WO PCT/US2006/028326 patent/WO2007014011A2/en active Application Filing
- 2006-07-21 ES ES06788078.1T patent/ES2481402T3/es active Active
- 2006-07-21 EP EP06788078.1A patent/EP1912636B1/de active Active
- 2006-07-21 AU AU2006272837A patent/AU2006272837B2/en not_active Ceased
-
2008
- 2008-02-03 IL IL189201A patent/IL189201A/en not_active IP Right Cessation
- 2008-02-21 KR KR1020087004227A patent/KR101377688B1/ko active IP Right Grant
-
2010
- 2010-01-07 HK HK10100120.1A patent/HK1134436A1/xx not_active IP Right Cessation
-
2014
- 2014-07-16 CY CY20141100532T patent/CY1118055T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006272837B2 (en) | 2012-08-23 |
IL189201A (en) | 2014-05-28 |
PL1912636T3 (pl) | 2015-02-27 |
KR20080068637A (ko) | 2008-07-23 |
EP1912636A4 (de) | 2009-11-18 |
IL189201A0 (en) | 2009-02-11 |
WO2007014011A3 (en) | 2009-04-23 |
KR101377688B1 (ko) | 2014-03-25 |
MX2008002114A (es) | 2008-04-17 |
WO2007014011A2 (en) | 2007-02-01 |
ES2481402T3 (es) | 2014-07-30 |
EP1912636A2 (de) | 2008-04-23 |
PT1912636E (pt) | 2014-07-24 |
CA2618218A1 (en) | 2007-02-01 |
DK1912636T3 (da) | 2014-07-21 |
CY1118055T1 (el) | 2017-06-28 |
AU2006272837A1 (en) | 2007-02-01 |
CA2618218C (en) | 2015-06-30 |
EP1912636B1 (de) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1134436A1 (en) | N-(arylamino)-sulfonamide inhibitors of mek mek | |
ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
IL180018A0 (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase | |
EP1756092A4 (de) | Neue inhibitoren von rho-kinasen | |
IL192134A0 (en) | Soft protease inhibitors and pro-soft forms thereof | |
IL179398A0 (en) | Dpp-ib inhibitors | |
ZA200802867B (en) | Fap inhibitors | |
DK2439205T3 (da) | Carboxamidforbindelser og deres anvendelse som calpaininhibitorer | |
HRP20130810T1 (en) | Sulphonylpyrroles as hdac inhibitors | |
IL187695A0 (en) | N-(pyridin-2-yl)-sulfonamide derivatives | |
IL190372A0 (en) | Biaryl substituted heterocycle inhibitors of lta4h | |
ZA200801351B (en) | Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors | |
EP1750696B1 (de) | Resistenzvermeidende inhibitoren für retrovirale proteasen | |
EP1732891A4 (de) | Resistenzvermeidende inhibitoren für retrovirale proteasen | |
HK1099300A1 (en) | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | |
EP1839669A4 (de) | Neue angiogenesehemmer | |
GB0400290D0 (en) | dUTPase inhibitors | |
EP1921078A4 (de) | Multikinaseinhibitor | |
EP1910272A4 (de) | Renininhibitoren | |
EP1789055A4 (de) | Thiazolopyridin-kinase-hemmer | |
ZA200801443B (en) | N-(arylamino)-sulfonamide inhibitors of MEK | |
GB0515327D0 (en) | Comt inhibitors | |
GB0421355D0 (en) | Inhibitors | |
EP1912662A4 (de) | Peptid-deformylase-hemmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220724 |